News

Releases included below may include references to both on-label and off-label usage of the HeartLight® Endoscopic Ablation System.
16
Mar
2021
16 Mar 2021

CardioFocus® Invited To Participate At The Oppenheimer 31st Annual Healthcare Conference

MARLBOROUGH, Mass., March 16, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer and President Burke T. Barrett will present at the Oppenheimer 31st Annual Healthcare Conference, being held virtually March 16-18, 2021.

25
Feb
2021
25 Feb 2021

CardioFocus® Announces The Publication Of HeartLight X3 Pivotal Study Data

MARLBOROUGH, Mass., Feb. 25, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that results from its HeartLight® X3 Pivotal Study were published in the premier journal Circulation: Arrhythmia and Electrophysiology (CircEP), which features articles related to research in and the practice of clinical cardiac electrophysiology and the diagnosis and management of […]

02
Feb
2021
02 Feb 2021

CardioFocus® Announces Expanded Partnership With Japan Lifeline

MARLBOROUGH, Mass., Feb. 2, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced today that it has expanded its existing partnership agreement with Japan Lifeline Co., Ltd. (JLL). The agreement extends the timeframe of the existing distribution agreement for Japan, as well as South Korea and Taiwan. The updated partnership also results in […]

12
Jan
2021
12 Jan 2021

CardioFocus® Invited To Participate In 23rd Annual ICR Conference And Needham Virtual Growth Conference

MARLBOROUGH, Mass., Jan. 12, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference, being held virtually January 11-14, 2021.

11
Jan
2021
11 Jan 2021

CardioFocus® Announces Expanded Distribution Partnership With MicroPort CRM To Include Spain And Portugal

MARLBOROUGH, Mass., Jan. 11, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal.

15
Dec
2020
15 Dec 2020

CardioFocus® Announces 10,000 Patients Treated Worldwide

MARLBOROUGH, Mass., June 16, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that more than 10,000 patients worldwide have been treated with the HeartLight® Endoscopic Ablation System.

16
Jun
2020
16 Jun 2020

CardioFocus® Announces Initial Commercial Procedures Following US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation

MARLBOROUGH, Mass., June 16, 2020 /PRNewswire/ — CardioFocus, Inc., today announced that the first U.S. patients have been treated commercially with the recently-approved HeartLight X3 Endoscopic Ablation System. The revolutionary cardiac ablation technology is designed to treat drug refractory, symptomatic paroxysmal atrial fibrillation (AFib), the most common heart rhythm disorder.

12
May
2020
12 May 2020

CardioFocus® Announces US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation

MARLBOROUGH, Mass., May 12, 2020 /PRNewswire/ — CardioFocus, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation (PAF).

04
Feb
2020
04 Feb 2020

CardioFocus® Announces US FDA PMA Supplement Submission for the Breakthrough HeartLight® X3 Endoscopic Ablation System

MARLBOROUGH, Mass., February 4, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the company has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for the treatment of AFib. This supplement […]

22
Jan
2020
22 Jan 2020

CardioFocus® Names Burke T. Barrett as Chief Executive Officer

MARLBOROUGH, Mass., January 22, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the Company’s Board of Directors has promoted Burke T. Barrett to the position of Chief Executive Officer (CEO), effective January 19, 2020. Mr. Barrett previously served as CardioFocus’ President and Chief […]